阿克提斯肿瘤 AKTS
$15.82 +$0.97 (+6.53%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $15.82 0.00%
开盘$14.85
昨收$14.85
当日区间$14.82 – $16.10
成交量362.9K
市值$879.90M
市盈率（TTM）–
股息率–
AKTS 相关新闻
匹配 Aktis Oncology 或代码 AKTS 的头条新闻，按最新排序。
- Oppenheimer Initiates Aktis Oncology(AKTS.US) With Buy Rating, Announces Target Price $40
- Wedbush Initiates Aktis Oncology(AKTS.US) With Buy Rating, Announces Target Price $35
- J.P. Morgan Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $33
- Analysts Have Conflicting Sentiments on These NA Companies: Aktis Oncology, Inc. (AKTS), Bullish (BLSH) and SanDisk Corp (SNDK) 正面
- William Blair Maintains Aktis Oncology(AKTS.US) With Buy Rating
- Aktis Oncology, Inc. (AKTS) Receives a Buy From Bank of America Securities
- Analysts Are Bullish on Top NA Stocks: Aktis Oncology, Inc. (AKTS), Yesway Inc Class A (YSWY) 正面
- BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34
- J.P. Morgan Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $33 正面
- J.P. Morgan Keeps Their Buy Rating on Aktis Oncology, Inc. (AKTS)
- H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $35
- H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $35 正面
- Raymond James Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $40
- Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS)
- William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating
暂无评论——快来第一个聊聊 AKTS。